文献速递炎症性肠病

克罗恩病乌司奴单抗生物类似药转换的临床结局:USBIOS-意大利炎症性肠病研究组研究

Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: The USBIOS-Italian Group for the Study of Inflammatory Bowel Disease Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-08-27

该前瞻性观察队列在意大利18个中心纳入462例临床缓解的克罗恩病患者,比较采购驱动的乌司奴单抗生物类似药转换(337例)与继续原研药(125例)的6个月结局。扩展临床成功在转换组为92.2%、对照组为92.7%,风险差-0.5%(95%CI -5.9至4.9),满足非劣效界值-15%。

要点

  • 临床稳定克罗恩病患者中,乌司奴单抗生物类似药转换6个月有效性与安全性与原研药相似。
  • 转换组扩展临床成功92.2%,对照组92.7%,风险差-0.5%满足非劣效。
  • 生物类似药持续率93.7%,转回原研药仅1.2%,转换后报告2例不良事件。

核心结论

  • 在临床稳定的克罗恩病患者中,采购驱动的乌司奴单抗生物类似药转换6个月有效性与安全性与继续原研药治疗相似。

研究设计与样本

  • 前瞻性观察队列研究,意大利18个中心,纳入462例临床缓解(Harvey-Bradshaw指数<5)且无激素≥8个月原研乌司奴单抗治疗的成人克罗恩病患者。
  • 337例转换为3种获批生物类似药之一,125例继续原研药;仅4例(0.9%)接受每4周给药。
  • 主要终点为扩展临床成功,非劣效界值-15%。

主要发现

  • 扩展临床成功在转换组为306/332例(92.2%),对照组为114/123例(92.7%);风险差-0.5%(95%CI -5.9至4.9),满足非劣效。
  • 方案定义的3组分复合终点及倾向评分加权后结果一致。
  • 生物类似药持续率93.7%,转回原研药发生率1.2%;转换后报告2例不良事件。

关键数值与推荐

  • 扩展临床成功定义:临床缓解且未使用全身糖皮质激素、未停用抗IL-12/23、无IBD相关住院或肠道手术。
  • 非劣效界值:-15%。

临床怎么用

  • 对于临床稳定且无激素维持的克罗恩病患者,采购驱动的乌司奴单抗生物类似药转换在6个月内可考虑作为继续原研药的替代方案。
  • 需注意每4周给药患者的数据有限,长期结局仍需进一步研究。

局限性

  • 观察性设计,非随机对照。
  • 随访仅6个月。
  • 每4周给药患者极少(仅4例,0.9%),该亚组证据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Controlled real-world evidence on nonmedical switching from reference ustekinumab to biosimilars in Crohn's disease (CD) is limited. We compared 6-month outcomes after switching vs continued reference treatment. METHODS: In this prospective observational cohort at 18 Italian centers, adults with CD in clinical remission (Harvey-Bradshaw Index <5) and steroid-free for ≥8 months of reference ustekinumab, underwent a procurement-driven switch to 1 of 3 approved biosimilars or continued reference treatment. The expanded clinical success end point required clinical remission without systemic corticosteroids, anti-interleukin12 or 23 discontinuation, inflammatory bowel disease-related hospitalization, or intestinal surgery. The protocol-specified noninferiority margin was -15%. RESULTS: Among 462 patients, 337 switched and 125 continued reference ustekinumab; only 4 (0.9%) received every-4-week dosing. Expanded clinical success occurred in 306 of 332 switched patients (92.2%) and 114 of 123 controls (92.7%; risk difference, -0.5%, 95% confidence interval, -5.9 to 4.9), meeting the noninferiority criterion. Results were consistent for the protocol-defined 3-component composite and after propensity-score weighting. Biosimilar persistence was 93.7%; switch-back occurred in 1.2%. Two adverse events were reported after switching. CONCLUSIONS: In clinically stable CD, the observed 6-month effectiveness and safety after procurement-driven ustekinumab biosimilar switching were similar to continued reference treatment. Longer-term studies, particularly in patients receiving every-4-week dosing, are needed.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ribaldone DG, Tribocco E, Scaldaferri F, et al. Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: The USBIOS-Italian Group for the Study of Inflammatory Bowel Disease Study. Clin Gastroenterol Hepatol. 2026. PMID: 42660257. doi:10.1016/j.cgh.2026.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。